Parathyroid Assessment of Symptoms French Version
Condition(s) studied
Investigational drug(s) / intervention(s)
SF-36 questionnaire French version and PAS.fr questionnaire: Patients will receive both the SF-36 questionnaire (control generic questionnaire for QoL evaluation validated in French language) and the PAS.fr questionnaire at the designated time (before surgery, 6, 12 or 36 months after surgery) during the consultation, or by mail. For concurrent validation of the PAS.fr questionnaire, a second questionnaire will be sent to the patients 2-4 weeks thereafter.
Study summary
Primary hyperparathyroidism has been associated with an impaired quality of life. Surgery has been suggested to improve this outcome in patients with baseline quality of life impairment; however, few studies have used specific tool for quality of life assessment this pathology, none being validated in French version. The aim of this study is to validate the parathyroid assessment of symptoms (PAS) questionnaire in French language to evaluate quality of life impairment and the impact of surgery in patients with primary hyperparathyroidism.
Eligibility
Primary outcome measure(s)
- Validate the unidimensionality of the PAS.fr for assessing quality of life in PHPT patients — 4 weeks
The unidimensionality of the 13 items of the PAS.fr questionnaire will be determined based on their suitability for a confirmatory factor analysis (CFA). Suitability will be judged based on the suitability coefficients RMSEA, TLI and CFI. The adequation will be judged acceptable if RMSEA\<0.08, CFI\>0.9 and TLI\>0.9 and will be judged good if RMSEA\<0.05, CFI\>0.95 and TLI\>0.95.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Nantes University Hospital | Nantes | Loire-Atlantique | Recruiting |
More Nantes University Hospital trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06450431 on ClinicalTrials.gov ↗ ← All trials in France